2026年后通用Ozempic专利到期的加拿大公司;美国价格商谈刺激Novo Nordisk股票下跌。 Canadian firm to make generic Ozempic post-2026 patent expiry; U.S. price talk spurs Novo Nordisk stock drop.

加拿大Vimy Pharma公司计划在2026年初专利到期后开始国内制造业,计划制作含有酸的Ozempic通用版Ozempic,以提高加拿大的可负担性和可获得性。 Canadian company Vimy Pharma plans to produce a generic version of Ozempic, containing semaglutide, to improve affordability and access in Canada, with domestic manufacturing set to begin after patent expiry in early 2026. 2025年10月17日诺沃·诺迪斯克(Novo Nordisk)股价下跌5.6%至7%, 前总统唐纳德·特朗普(Donald Trump)宣布美国对欧兹姆比(Ozempic)等减重药品的价格可大幅下跌至每月150美元, 引用“最有利的国家”政策。 Meanwhile, Novo Nordisk shares dropped 5.6% to 7% on October 17, 2025, following former President Donald Trump’s announcement that U.S. prices for weight-loss drugs like Ozempic could be slashed to $150 per month, citing the “most favored nation” policy. 在白宫活动期间发表的这些言论引起了投资者对监管压力和价格改革的担忧,尽管没有立即颁布政策改变。 The remarks, made during a White House event, triggered investor concerns over regulatory pressure and pricing reforms, though no immediate policy changes were enacted. 作为回应,诺沃·诺迪斯克任命AbbVie前执行官Greg Miley担任新的公司事务主管,负责政治监督。 Greg Miley曾是AbbVie执行官,具有丰富的美国政府事务经验。 In response, Novo Nordisk appointed Greg Miley, a former AbbVie executive with strong U.S. government affairs experience, as its new head of corporate affairs to navigate political scrutiny. 该公司也正在进行重大改组,包括裁减9 000个工作岗位。 The company is also undergoing a major restructuring, including 9,000 job cuts. 美国食品和药物管理局启动试点计划, 加快对9种优先药物的审查, The FDA launched a pilot program to accelerate reviews of nine high-priority drugs, including an infertility treatment, to address critical public health issues.